Home' Australian Pharmacist : Australian Pharmacist May 2015 Contents Australian Pharmacist May 2015 I ©Pharmaceutical Society of Australia Ltd. 75
that re ects
Australia (CMA) has called for
regulation that reflects risk,
protects consumers, safeguards
quality and promotes industry
best practice in response to the
Government's Expert Review of
Medicines and Medical Devices
Chief Executive Officer Carl Gibson said
that CMA promotes appropriate industry
regulation to ensure consumers have
access to complementary medicines of
the highest quality.
'The complementary medicines industry
calls for regulation of complementary
healthcare products that is appropriate
and commensurate with the risk profile
of these products.'
CMA is recommending a package of
measures, including: Retaining but
simplifying the existing regulatory
framework, strengthening the TGA
Complementary Medicines Branch with
sufficient resources and sector specific
expertise, cutting regulatory duplication
and provide faster access to new listable
substances with mutual recognition of
overseas regulators, a new registration
pathway for low risk complementary
medicines making higher level health
claims, and simplifying the Australian
Register of Therapeutic Goods for listed
Mr Gibson also warned of the
unintended consequences of excessive
removal of regulation. 'Australian
complementary medicines are
manufactured and regulated to the
highest standards. We don't want to
throw the baby out with the bathwater,
but we can make the current system
work better, faster and cheaper without
sacrificing our growing export market,'
Mr Gibson said.
The sun sets on Ranbaxy
Sun Pharmaceutical Industries last
month began integrating Ranbaxy's
business following the successful
closure of its merger.
According to Sun Pharma the
integration, will focus on supporting
Sun Pharma Chairman Israel Makov said:
'The combined entity will capitalise on the
expanded global footprint and enhance
our dominance as a world leader in the
specialty generics landscape.
'Sun remains committed to
uncompromised product quality,
100% compliance and promotes
innovation to create the most
dynamic global specialty generics
pharmaceutical company. We believe
that our shareholders, customers and
employees will share our excitement in
the potential of this combination'.
A national health check
This month the National Stroke
Foundation is partnering with
Chemmart to take the nation's blood
pressure on 6 May.
They are setting up free health checks
in capital city sites and televising them
live on the Seven Network's The Morning
Show. This year the aim is to give health
checks to more than 15,000 people
across the country.
According to the National Stroke
Foundation stroke kills more women
than breast cancer and more men
than prostate cancer and leaves tens
of thousands of Australians disabled.
Across the country there are almost
440,000 people living with the
devastating after-effects of stroke.
The health checks will be held at:
Adelaide -- Rundle Mall; Brisbane
-- Queen Street Mall; Melbourne --
Federation Square; Sydney -- Martin
Place; Perth -- Murray St Mall; Hobart --
Elizabeth St Mall.
PBS reforms 'saving billions'
The Federal Government will achieve
more than $16 billion in PBS savings
from 2010--18, while listings of new
medicines over this period will cost
only $6 billion according to Medicines
An analysis conducted by
PharmaDispatch, concluded there
would be government savings of more
than $2.70 for every $1 spent on new
medicines between 2010 and 2018.
MA CEO Tim James welcomed the
analysis and said it demonstrated
that ongoing PBS reforms were
generating billions of dollars in savings,
with enduring mechanisms to continue
the generation of savings.
'We know that successive reforms have
put the PBS on a stable footing and
continue to generate ongoing savings
for Government. This report adds further
to the large body of evidence that
shows PBS expenditure is sustainable,'
Mr James said.
'The May 2013 Victoria University report
showed PBS reforms will deliver more
than $20 billion of savings over the
period 2007--18, and most recently
the 2015 Intergenerational Report
(IGR) which acknowledged growth
in pharmaceutical expenditure will
remain stable, growing only modestly to
'With an established body of evidence
that shows the PBS is sustainable and
delivering major savings to government,
it is important now to ensure Australians
have timely access to new medicines,'
Mr James said.
Links Archive Australian Pharmacist April 2015 Australian Pharmacist June 2015 Navigation Previous Page Next Page